BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki T, Harders GE, Chen HH, Burnett JC. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension. 2011;57:201-207. [PMID: 21189408 DOI: 10.1161/hypertensionaha.110.160796] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Sangaralingham SJ, Kuhn M, Cannone V, Chen HH, Burnett JC. Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovasc Res 2023;118:3416-33. [PMID: 36004816 DOI: 10.1093/cvr/cvac125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Osorio JM, Espinoza-Pérez C, Rimassa-Taré C, Machuca V, Bustos JO, Vallejos M, Vargas H, Díaz-Araya G. Senescent cardiac fibroblasts: A key role in cardiac fibrosis. Biochim Biophys Acta Mol Basis Dis 2023;1869:166642. [PMID: 36669578 DOI: 10.1016/j.bbadis.2023.166642] [Reference Citation Analysis]
3 Nakagawa Y, Nishikimi T. CNP, the Third Natriuretic Peptide: Its Biology and Significance to the Cardiovascular System. Biology 2022;11:986. [DOI: 10.3390/biology11070986] [Reference Citation Analysis]
4 Shao S, Li X, Wang J. Research progress in natriuretic peptide receptor C and cardiovascular disease. Sci Sin -Vitae 2022;52:760-766. [DOI: 10.1360/ssv-2021-0270] [Reference Citation Analysis]
5 Hu P, Chen H, Wang LH, Jiang JB, Li JM, Tang MY, Guo YC, Zhu QF, Pu ZX, Lin XP, Ng S, Liu XB, Wang JA. Elevated N-terminal pro C-type natriuretic peptide is associated with mortality in patients undergoing transcatheter aortic valve replacement. BMC Cardiovasc Disord 2022;22:164. [PMID: 35413789 DOI: 10.1186/s12872-022-02615-8] [Reference Citation Analysis]
6 Murray K, Wahid M, Alagiakrishnan K, Senaratne J. Clinical electrophysiology of the aging heart. Expert Rev Cardiovasc Ther 2022;:1-17. [PMID: 35282746 DOI: 10.1080/14779072.2022.2045196] [Reference Citation Analysis]
7 Jansen HJ, Moghtadaei M, Rafferty SA, Rose RA. Atrial Fibrillation in Aging and Frail Mice: Modulation by Natriuretic Peptide Receptor C. Circ Arrhythm Electrophysiol 2021;14:e010077. [PMID: 34490788 DOI: 10.1161/CIRCEP.121.010077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Oneglia A, Nelson MD, Merz CNB. Sex Differences in Cardiovascular Aging and Heart Failure. Curr Heart Fail Rep 2020;17:409-23. [PMID: 32984923 DOI: 10.1007/s11897-020-00487-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
9 Salazar J, Rojas-Quintero J, Cano C, Pérez JL, Ramírez P, Carrasquero R, Torres W, Espinoza C, Chacín-González M, Bermúdez V. Neprilysin: A Potential Therapeutic Target of Arterial Hypertension? Curr Cardiol Rev 2020;16:25-35. [PMID: 31241018 DOI: 10.2174/1573403X15666190625160352] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
10 Savira F, Magaye R, Liew D, Reid C, Kelly DJ, Kompa AR, Sangaralingham SJ, Burnett JC Jr, Kaye D, Wang BH. Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. Br J Pharmacol 2020;177:2906-22. [PMID: 32250449 DOI: 10.1111/bph.15065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
11 Martin B, Gabris B, Barakat AF, Henry BL, Giannini M, Reddy RP, Wang X, Romero G, Salama G. Relaxin reverses maladaptive remodeling of the aged heart through Wnt-signaling. Sci Rep 2019;9:18545. [PMID: 31811156 DOI: 10.1038/s41598-019-53867-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
12 Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, Hernandez AF, Scott CG, Burnett JC Jr, Pereira NL. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail 2020;8:70-80. [PMID: 31392960 DOI: 10.1016/j.jchf.2019.07.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
13 Curtis AB, Karki R, Hattoum A, Sharma UC. Arrhythmias in Patients ≥80 Years of Age: Pathophysiology, Management, and Outcomes. J Am Coll Cardiol 2018;71:2041-57. [PMID: 29724357 DOI: 10.1016/j.jacc.2018.03.019] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 12.8] [Reference Citation Analysis]
14 Egom EE. Pulmonary Arterial Hypertension Due to NPR-C Mutation: A Novel Paradigm for Normal and Pathologic Remodeling? Int J Mol Sci 2019;20:E3063. [PMID: 31234560 DOI: 10.3390/ijms20123063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Moyes AJ, Hobbs AJ. C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int J Mol Sci 2019;20:E2281. [PMID: 31072047 DOI: 10.3390/ijms20092281] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 16.5] [Reference Citation Analysis]
16 Chen Y, Zheng Y, Iyer SR, Harders GE, Pan S, Chen HH, Ichiki T, Burnett JC Jr, Sangaralingham SJ. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. J Mol Cell Cardiol 2019;130:140-50. [PMID: 30954448 DOI: 10.1016/j.yjmcc.2019.03.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
17 Keng BMH, Gao F, Tan RS, Ewe SH, Teo LLY, Xie BQ, Goh GBB, Koh WP, Koh AS. N-Terminal pro C-Type Natriuretic Peptide (NTproCNP) and myocardial function in ageing. PLoS One 2018;13:e0209517. [PMID: 30566484 DOI: 10.1371/journal.pone.0209517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Martin B, Gabris-Weber BA, Reddy R, Romero G, Chattopadhyay A, Salama G. Relaxin reverses inflammatory and immune signals in aged hearts. PLoS One 2018;13:e0190935. [PMID: 29346407 DOI: 10.1371/journal.pone.0190935] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
19 Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng 2018;12:2. [PMID: 29344085 DOI: 10.1186/s13036-017-0093-0] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 14.8] [Reference Citation Analysis]
20 Nelson MD, Samuel TJ, Young BE, Rosenberry R, Fadel PJ. Cardiovascular Aging. Handbooks in Health, Work, and Disability 2018. [DOI: 10.1007/978-3-030-03916-5_9] [Reference Citation Analysis]
21 Vittorio TJ. Quit Smoking, Close Your Mouth, Drop the Fork and Get off the Couch. AOWMC 2017;7. [DOI: 10.15406/aowmc.2017.07.00208] [Reference Citation Analysis]
22 Jansen HJ, Moghtadaei M, Mackasey M, Rafferty SA, Bogachev O, Sapp JL, Howlett SE, Rose RA. Atrial structure, function and arrhythmogenesis in aged and frail mice. Sci Rep 2017;7:44336. [PMID: 28290548 DOI: 10.1038/srep44336] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
23 Patel H, Alkhawam H, Madanieh R, Shah N, Kosmas CE, Vittorio TJ. Aerobic vs anaerobic exercise training effects on the cardiovascular system. World J Cardiol 2017; 9(2): 134-138 [PMID: 28289526 DOI: 10.4330/wjc.v9.i2.134] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 14.7] [Reference Citation Analysis]
24 Khirmanov VN. The role of natriuretic peptides in regulation of cardiovascular system. Kardiol serdechno-sosud khir 2017;10:3. [DOI: 10.17116/kardio201710123-25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Moghtadaei M, Jansen HJ, Mackasey M, Rafferty SA, Bogachev O, Sapp JL, Howlett SE, Rose RA. The impacts of age and frailty on heart rate and sinoatrial node function. J Physiol 2016;594:7105-26. [PMID: 27598221 DOI: 10.1113/JP272979] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
26 Hu P, Liu SY, Zhang DD, Xu Y, Xia X. Urinary C-type natriuretic peptide excretion: a promising biomarker to detect underlying renal injury and remodeling both acutely and chronically. Biomark Med 2016;10:999-1008. [PMID: 27586401 DOI: 10.2217/bmm-2016-0089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Rog-Zielinska EA, Norris RA, Kohl P, Markwald R. The Living Scar--Cardiac Fibroblasts and the Injured Heart. Trends Mol Med 2016;22:99-114. [PMID: 26776094 DOI: 10.1016/j.molmed.2015.12.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 13.0] [Reference Citation Analysis]
28 Sangaralingham SJ, Wang BH, Huang L, Kumfu S, Ichiki T, Krum H, Burnett JC Jr. Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen. Peptides 2016;76:108-14. [PMID: 26774586 DOI: 10.1016/j.peptides.2016.01.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
29 Lee CY, Huntley BK, McCormick DJ, Ichiki T, Sangaralingham SJ, Lisy O, Burnett JC Jr. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother 2016;2:98-105. [PMID: 27340557 DOI: 10.1093/ehjcvp/pvv040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
30 Kerkelä R, Ulvila J, Magga J. Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. J Am Heart Assoc 2015;4:e002423. [PMID: 26508744 DOI: 10.1161/JAHA.115.002423] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 10.0] [Reference Citation Analysis]
31 McKie PM, Burnett JC Jr. Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure. Curr Heart Fail Rep 2015;12:7-14. [PMID: 25331110 DOI: 10.1007/s11897-014-0235-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
32 Lee J, Than M, Aldous S, Troughton R, Richards M, Pemberton CJ. CNP Signal Peptide in Patients with Cardiovascular Disease. Front Cardiovasc Med 2015;2:28. [PMID: 26664899 DOI: 10.3389/fcvm.2015.00028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
33 Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population. Hypertension 2015;65:1187-94. [PMID: 25895587 DOI: 10.1161/HYPERTENSIONAHA.115.05366] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
34 Burt JR, Zimmerman SL, Kamel IR, Halushka M, Bluemke DA. Myocardial t1 mapping: techniques and potential applications. Radiographics. 2014;34:377-395. [PMID: 24617686 DOI: 10.1148/rg.342125121] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 7.9] [Reference Citation Analysis]
35 Zakeri R, Burnett JC Jr, Sangaralingham SJ. Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling. Clin Chim Acta 2015;443:108-13. [PMID: 25512164 DOI: 10.1016/j.cca.2014.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
36 Buglioni A, Burnett JC Jr. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta 2015;443:3-8. [PMID: 25445413 DOI: 10.1016/j.cca.2014.10.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
37 Ichiki T, Schirger JA, Huntley BK, Brozovich FV, Maleszewski JJ, Sandberg SM, Sangaralingham SJ, Park SJ, Burnett JC Jr. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. J Mol Cell Cardiol 2014;75:199-205. [PMID: 25117468 DOI: 10.1016/j.yjmcc.2014.08.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
38 Akseki Temür H, Vardar SA, Demir M, Palabıyık O, Karaca A, Guksu Z, Ortanca A, Süt N. The alteration of NTproCNP plasma levels following anaerobic exercise in physically active young men. Anatol J Cardiol 2015;15:97-102. [PMID: 25252292 DOI: 10.5152/akd.2014.5204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Pereira NL, Redfield MM, Scott C, Tosakulwong N, Olson TM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. A functional genetic variant (N521D) in natriuretic peptide receptor 3 is associated with diastolic dysfunction: the prevalence of asymptomatic ventricular dysfunction study. PLoS One 2014;9:e85708. [PMID: 24465655 DOI: 10.1371/journal.pone.0085708] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
40 von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC Jr, Krum H. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013;6:594-605. [PMID: 23694773 DOI: 10.1161/CIRCHEARTFAILURE.112.000289] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 9.5] [Reference Citation Analysis]
41 Martin FL, Sangaralingham SJ, Huntley BK, McKie PM, Ichiki T, Chen HH, Korinek J, Harders GE, Burnett JC Jr. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One 2012;7:e52422. [PMID: 23272242 DOI: 10.1371/journal.pone.0052422] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
42 Ichiki T, Boerrigter G, Huntley BK, Sangaralingham SJ, McKie PM, Harty GJ, Harders GE, Burnett JC Jr. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol 2013;304:R102-9. [PMID: 23152112 DOI: 10.1152/ajpregu.00233.2012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
43 Hu P, Wang J, Zhao XQ, Hu B, Lu L, Qin YH. Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats. Mol Biol Rep 2013;40:1429-41. [PMID: 23073778 DOI: 10.1007/s11033-012-2186-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
44 Chaudhary KR, El-Sikhry H, Seubert JM. Mitochondria and the aging heart. J Geriatr Cardiol 2011;8:159-67. [PMID: 22783302 DOI: 10.3724/SP.J.1263.2011.00159] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
45 Sangaralingham SJ, Ritman EL, McKie PM, Ichiki T, Lerman A, Scott CG, Martin FL, Harders GE, Bellavia D, Burnett JC Jr. Cardiac micro-computed tomography imaging of the aging coronary vasculature. Circ Cardiovasc Imaging 2012;5:518-24. [PMID: 22679058 DOI: 10.1161/CIRCIMAGING.112.973057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
46 McKie PM, Ichiki T, Burnett JC Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep 2012;14:62-9. [PMID: 22135207 DOI: 10.1007/s11906-011-0244-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
47 Dai DF, Chen T, Johnson SC, Szeto H, Rabinovitch PS. Cardiac aging: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal 2012;16:1492-526. [PMID: 22229339 DOI: 10.1089/ars.2011.4179] [Cited by in Crossref: 199] [Cited by in F6Publishing: 202] [Article Influence: 18.1] [Reference Citation Analysis]
48 Fujimoto N, Hastings JL, Bhella PS, Shibata S, Gandhi NK, Carrick-Ranson G, Palmer D, Levine BD. Effect of ageing on left ventricular compliance and distensibility in healthy sedentary humans. J Physiol 2012;590:1871-80. [PMID: 22331419 DOI: 10.1113/jphysiol.2011.218271] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 7.6] [Reference Citation Analysis]
49 Sangaralingham SJ, Heublein DM, Grande JP, Cataliotti A, Rule AD, McKie PM, Martin FL, Burnett JC Jr. Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. Am J Physiol Renal Physiol 2011;301:F943-52. [PMID: 21865266 DOI: 10.1152/ajprenal.00170.2011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
50 Calvieri C, Rubattu S, Volpe M. Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. J Mol Med (Berl) 2012;90:5-13. [PMID: 21826523 DOI: 10.1007/s00109-011-0801-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]